STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes
This was supposed to be the new Biogen. Instead, the company's board saddled CEO Chris Viehbacher with the first crisis of his tenure at the company.
Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way
